In vivo inhibition of angiogenesis by a soluble form of melanotransferrin
Authors:
- Michel DemeuleMDMichel Demeule
- Richard BéliveauRBRichard Béliveau
Open Access
- 8 July 2006
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 28 (2) , 280-288
Abstract
Melanotransferrin (MTf), the membrane-bound human melanoma antigen p97, binds to plasminogen and stimulates its activation, thus regulating a crucial step involved in angiogenesis. In our study, a truncated soluble form of MTf (sMTf) inhibits, in a dose-dependent manner, the in vitro tubulogenesis of human umbilical vessel endothelial cells (HUVEC) induced by media conditioned with MTf-expressing cells. Following these results, we used the in vivo Matrigel™ plug angiogenesis assay to investigate whether truncated sMTf could inhibit neovascularization in mice. We found that basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and MTf-expressing cells strongly stimulate in vivo Matrigel™ neovascularization. However, subcutaneous (s.c.) administration of truncated sMTf inhibits both bFGF- and VEGF- as well as human melanoma SK-Mel-28-induced angiogenesis. This inhibition was dependent on the truncated sMTf concentration and reached maximal inhibition at 40 mg/kg/week. Furthermore, we found that a single s.c. injection of truncated sMTf into nude mice at 5 mg/kg produced a maximal blood concentration of ∼40 nM, which is comparable with the level required to inhibit in vitro HUVEC tubulogenesis. Overall, our results strongly suggest that s.c. administration of truncated sMTf may provide a novel therapeutic strategy for the treatment of angiogenesis-related disorders.Keywords
This publication has 30 references indexed in Scilit:
- Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: A key phenomenon for cell invasionExperimental Cell Research, 2005
- ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer modelInternational Journal of Cancer, 2005
- Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic systemBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2005
- Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and humanBiochimica et Biophysica Acta (BBA) - General Subjects, 2005
- In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragmentExperimental and Molecular Pathology, 2004
- Inhibitory effect of soluble PDGF-β receptor in culture-activated hepatic stellate cellsBiochemical and Biophysical Research Communications, 2004
- Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cellsThe Prostate, 2004
- Role of plasminogen activator-plasmin system in tumor angiogenesisCellular and Molecular Life Sciences, 2003
- Response of bovine endothelial cells to FGF‐2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesisJournal of Cellular Biochemistry, 2001
- AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMACytokine, 2000